Physician profile
Brian M Thomas
NPI 1992948392
$1,207.90
in general payments reported to CMS, 2019-2025
18 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.85 · 2021: $11.04 · 2022: $41.97 · 2023: $110 · 2024: $663 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.10 |
| Education | $193.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $241.79 | 2024-2025 | Injectafer, Enhertu, Vanflyta |
| Pfizer INC. | $190.26 | 2023-2025 | |
| Incyte Corporation | $119.16 | 2024 | Monjuvi |
| Becton, Dickinson and Company | $103.19 | 2025 | Arista |
| Abbvie INC. | $99.99 | 2024 | |
| Astellas Pharma US INC | $75.24 | 2023-2024 | Padcev, Xtandi |
| Novartis Pharmaceuticals Corporation | $72.87 | 2024 | |
| Eisai INC. | $64.38 | 2024-2025 | |
| Genentech USA, INC. | $51.85 | 2019 | |
| Array Biopharma INC | $33.11 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Genzyme Corporation | $29.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.80 | 2021-2025 | Opdivo |
| Stemline Therapeutics INC. | $20.38 | 2024 | Orserdu |
| Gilead Sciences, INC. | $17.79 | 2025 | Trodelvy |
| Seagen INC. | $17.03 | 2023 | Padcev |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $16.33 | 2023 | |
| Coherus Oncology, INC. | $13.76 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.